Entecavir Interacts with Influx Transporters hOAT1, hCNT2, hCNT3, but Not with hOCT2: The Potential for Renal Transporter-Mediated Cytotoxicity and Drug–Drug Interactions

Entecavir (ETV) is one of the most potent agents for the treatment of the hepatitis B viral infection. The drug is principally eliminated by the kidney. The goal of this study was to investigate the potential of ETV to interact in vitro with the renal SLC transporters hOAT1, hOCT2, hCNT2 and hCNT3....

Descripción completa

Detalles Bibliográficos
Autores principales: Mandíková, Jana, Volková, Marie, Pávek, Petr, Navrátilová, Lucie, Hyršová, Lucie, Janeba, Zlatko, Pavlík, Jan, Bárta, Pavel, Trejtnar, František
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700268/
https://www.ncbi.nlm.nih.gov/pubmed/26779022
http://dx.doi.org/10.3389/fphar.2015.00304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700268/
https://www.ncbi.nlm.nih.gov/pubmed/26779022
http://dx.doi.org/10.3389/fphar.2015.00304

Ejemplares similares